Scientists warn on "dead space" as pharma giants shun neuropsych

European experts are sounding an alarm about the recent pullout of GlaxoSmithKline and AstraZeneca from the brain disorder arena.  David Nutt, a professor Imperial College London, and Oxford's Guy Goodwin are calling for a rapid response to what they term a collapse in R&D spending in the field.

"What we have forgotten, and must not forget, is if we stop this research we will have a dead space of 20 to 30 years before we can re-tool again," Nutt tells The Guardian. "Despite the public health imperative, not only has EU research funding remained very low, but--even worse--big pharma is increasingly coming to see research into better neuropsychiatric drug targets as economically non-viable."

That effectively sums up the position of GSK's Andrew Witty, who has explained that the huge risk associated with developing new drugs for neuroscientists is just too high to justify the investment necessary. The Guardian notes that the average time it takes to develop a new drug for a brain disorder is 13 years-considerably higher than the average program and significantly more expensive.

So the experts are seeking a solution. They want the drug companies which are abandoning the field to offer up the work they have to academic researchers in the field. And they want some "insurance" from authorities to protect those companies from any future damages that could arise if they misfire, as has been seen in the past.

- here's the article from The Guardian

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.